Gensight Biologics SA (SIGHT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gensight Biologics SA (SIGHT) has a cash flow conversion efficiency ratio of 0.260x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-6.49 Million ≈ $-7.59 Million USD) by net assets (€-24.94 Million ≈ $-29.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Gensight Biologics SA (SIGHT) market capitalisation for the company's overall valuation and market capitalisation.
Gensight Biologics SA - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Gensight Biologics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Gensight Biologics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gensight Biologics SA ranked by their cash flow conversion efficiency. See Gensight Biologics SA (SIGHT) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sustainable Power & Infrastructure Split Corp
TO:PWI
|
0.089x |
|
Viva Gold Corp
V:VAU
|
-0.386x |
|
Ihuman Inc
NYSE:IH
|
0.193x |
|
Tien Wah Press Holdings Bhd
KLSE:7374
|
0.040x |
|
Black Dragon Gold Corp
AU:BDG
|
0.214x |
|
Chinese People Holdings Company Limited
F:KEH
|
0.006x |
|
Vertex Minerals Ltd
AU:VTX
|
-0.175x |
|
Scope Industries Bhd
KLSE:0028
|
0.057x |
Annual Cash Flow Conversion Efficiency for Gensight Biologics SA (2013–2025)
The table below shows the annual cash flow conversion efficiency of Gensight Biologics SA from 2013 to 2025. View SIGHT stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-24.94 Million ≈ $-29.16 Million |
€-9.38 Million ≈ $-10.96 Million |
0.376x | -21.76% |
| 2024-12-31 | €-26.92 Million ≈ $-31.47 Million |
€-12.94 Million ≈ $-15.12 Million |
0.481x | -40.18% |
| 2023-12-31 | €-30.70 Million ≈ $-35.89 Million |
€-24.66 Million ≈ $-28.83 Million |
0.803x | -63.64% |
| 2022-12-31 | €-15.28 Million ≈ $-17.86 Million |
€-33.75 Million ≈ $-39.46 Million |
2.209x | +306.10% |
| 2021-12-31 | €15.99 Million ≈ $18.69 Million |
€-17.14 Million ≈ $-20.04 Million |
-1.072x | +16.87% |
| 2020-12-31 | €11.67 Million ≈ $13.64 Million |
€-15.04 Million ≈ $-17.59 Million |
-1.289x | +46.12% |
| 2019-12-31 | €11.75 Million ≈ $13.73 Million |
€-28.11 Million ≈ $-32.87 Million |
-2.393x | -101.28% |
| 2018-12-31 | €23.87 Million ≈ $27.91 Million |
€-28.38 Million ≈ $-33.18 Million |
-1.189x | -248.17% |
| 2017-12-31 | €55.00 Million ≈ $64.30 Million |
€-18.78 Million ≈ $-21.96 Million |
-0.342x | +7.26% |
| 2016-12-31 | €53.34 Million ≈ $62.36 Million |
€-19.64 Million ≈ $-22.96 Million |
-0.368x | +10.71% |
| 2015-12-31 | €29.33 Million ≈ $34.29 Million |
€-12.09 Million ≈ $-14.14 Million |
-0.412x | +20.91% |
| 2014-12-31 | €10.58 Million ≈ $12.37 Million |
€-5.52 Million ≈ $-6.45 Million |
-0.521x | -353.65% |
| 2013-12-31 | €16.97 Million ≈ $19.83 Million |
€-1.95 Million ≈ $-2.28 Million |
-0.115x | -- |
About Gensight Biologics SA
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV… Read more